SEP 20, 2019 5:36 PM PDT

Remarkable Results From First Gene Therapy for Glycogen Storage Disease

WRITTEN BY: Carmen Leitch

Dr. David Weinstein of the University of Connecticut School of Medicine and Connecticut Children's has presented the results from a one-year clinical trial testing a new gene therapy as a treatment for glycogen storage disease (GSD). Reporting at the Association for Glycogen Storage Disease's 41st Annual Conference, the results were called “remarkable.”

A subset of GSD, the rare genetic disorder GSD type Ia is caused by a mutation in a gene encoding for an enzyme, glucose-6-phosphatase-α, which controls the release of sugar from the liver. Blood sugar drops to dangerously low levels in affected individuals, and they constantly require cornstarch to feed their body’s need for glucose. It affects them all their lives, and missing a dose may cause a seizure or death.

The gene therapy was administered to three patients in 2018. In it, an injection to the bloodstream delivers a normal copy of the defective gene to the liver using a virus. The dysfunctional enzyme is replaced and the body can control glucose levels again.

A year after receiving an infusion of GSD vaccine, patient Jerrod Watts has been able to stop consuming cornstarch every day. His blood glucose is regulated normally, he has more strength and energy and has lost weight. Before the trial, he was ingesting over 400 grams (nearly one pound) of cornstarch on a daily basis.

"The clinical trial is going better than expected. The therapy is transforming patient lives," said Weinstein. "We have seen all of the patients wean their therapy with some already discontinuing treatment. Missed cornstarch doses no longer are resulting in hypoglycemia, which previously could have been life-threatening."

The researchers were surprised by the results of the study. "We were just making sure it was safe for humans to take, that was our initial goal. The results are way beyond my imagination," said Weinstein. "The patients who are finishing the first year got what we all thought was a test dose -- one-third strength -- yet the response has been dramatic. They can now go through the night without any treatment and they wake up clinically well."

Jerrod Watts, a patient enrolled in the first clinical trial for Glycogen Storage Disease, chats with lead investigator Dr. David Weinsten. Photos taken in the dedicated Glycogen Storage Disease Unit at UConn Health. / Credit:Tina Encarnacion/UConn Health

"The main thing I want to do is inspire hope. One of the biggest reliefs from this gene therapy is I can now sleep through the night without worrying about dying in the middle of the night. I wake up six to seven hours later with normal blood sugar," Watts said. "I'm living, breathing proof that there is a light at the end of the tunnel with GSD. I'm a completely different person now that I was a year ago. I feel like I can live a normal life and I can do anything I want to do now."

He had a message for other patients: "Please don't give up hope."

The other two trial participants are also seeing good results. They have been able to reduce their cornstarch intake.

"What's exciting is if it works this well with the low dose, what does the future hold?" said Weinstein. "If the patients are already coming off cornstarch and the labs are getting better, we just hope it will be even faster and more dramatic with the higher dose."

"This gene therapy treatment is something we've worked on for 21 years. This means so much to the glycogen storage disease community," noted Weinstein. "To see patients off cornstarch and doing so well really is a culmination of an incredible journey ... We feel like we're living history."

Sources: AAAS/Eurekalert! via University of Connecticut

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
APR 29, 2021
Clinical & Molecular DX
We've Now Collected Over 1 Million Coronavirus Sequences
APR 29, 2021
We've Now Collected Over 1 Million Coronavirus Sequences
Over 1.2 million genome sequences collected from 172 countries have been uploaded to a data-sharing site over the course ...
APR 25, 2021
Genetics & Genomics
How Did the Chernobyl Disaster Affect Human Health?
APR 25, 2021
How Did the Chernobyl Disaster Affect Human Health?
It's been about 35 years since the disaster at the Chernobyl nuclear power plant. Now researchers have investigated whet ...
MAY 09, 2021
Genetics & Genomics
Another Neurodevelopmental Disorder is Discovered
MAY 09, 2021
Another Neurodevelopmental Disorder is Discovered
Researchers are identifying more rare disorders because of advances in genetic sequencing technologies, which have made ...
MAY 26, 2021
Genetics & Genomics
Connecting Bacterial Genes to Human Disease
MAY 26, 2021
Connecting Bacterial Genes to Human Disease
This kind of research gets us closer to using fecal samples to get a snapshot of the microbiome, and make disease risk p ...
JUN 06, 2021
Genetics & Genomics
How Autism-Associated Mutations in One Gene Impact the Brain
JUN 06, 2021
How Autism-Associated Mutations in One Gene Impact the Brain
Autism spectrum disorder is complex; it presents differently in different patients and may be influenced by many factors ...
JUL 15, 2021
Cell & Molecular Biology
Do Microbial Pathogens Have an Epigenetic Memory?
JUL 15, 2021
Do Microbial Pathogens Have an Epigenetic Memory?
Epigenetics are the parts of the genome that can affect the activity of genes but don't involve making changes to th ...
Loading Comments...